Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Ceftolozane/tazobactam: place in therapy.

Author information

Affiliations

  • 1. Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia and Department of Health Sciences , University of Genoa , Genoa , Italy.
      Authors
    • Giacobbe DR 1
    • Del Bono V 1
    • Viscoli C 1
    (3 authors)
  • 2. Infectious Diseases Clinic, Department of Medicine , University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia , Udine , Italy.
      Authors
    • Bassetti M 2
    (1 author)
  • 3. Department of Medical Sciences , University of Turin, Infectious Diseases, City of Health and Sciences , Turin , Italy.
      Authors
    • De Rosa FG 3
    (1 author)
  • 4. Department of Surgical and Morphological Sciences of Clinical Medicine , University of Insubria , Varese , Italy.
      Authors
    • Grossi PA 4
    (1 author)
  • 5. Infectious Diseases Clinic , Nuovo Santa Chiara University Hospital, Azienda Ospedaliera Universitaria Pisana , Pisa , Italy.
      Authors
    • Menichetti F 5
    (1 author)
    • Show all (9)

ORCIDs linked to this article

Expert Review of Anti-infective Therapy, 09 Mar 2018, 16(4):307-320
https://doi.org/10.1080/14787210.2018.1447381 PMID: 29493397 

Review

Abstract 

Introduction

Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians' confidence in using it for indications other than cIAI and cUTI.

Full text links 

Read article at publisher's site: https://doi.org/10.1080/14787210.2018.1447381

Read article for free, from open access legal sources, via Unpaywall: https://iris.unito.it/bitstream/2318/1686331/1/Ceftolozane%20ISGRI%20Expert%20Review%202018%20Giacobbe%20pdf%20editoriale.pdfUnpaywall

References 

Articles referenced by this article (110)

Show 10 more references (10 of 110)

Citations & impact 

Impact metrics

64
Citations
Jump to Citations
1
Data citation
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/33828964
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/33828964

Article citations

Go to all (64) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

MSD Italia Srl